<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076699</url>
  </required_header>
  <id_info>
    <org_study_id>RVG-09-005</org_study_id>
    <nct_id>NCT01076699</nct_id>
  </id_info>
  <brief_title>A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)</brief_title>
  <official_title>A Phase 2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Four-Arm Trial to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo for the Treatment of Abdominal Pain in Patients With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revogenex, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revogenex, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if RVX-100 is safe and effective in treating acute&#xD;
      abdominal pain in patients with irritable bowel syndrome accompanied by diarrhea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    recruiting/enrolling participants has halted prematurely but potentially will resume Oct&#xD;
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in weekly average abdominal pain severity score from baseline.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in weekly average Abdominal Pain Severity score from baseline to week 8</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response, based on abdominal pain severity scores.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in each treatment arm who are weekly responders.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in each treatment arm who are end-of-treatment responders</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pain-free days per week, based on responses to the Abdominal Pain Severity scale</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel urgency</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool consistency</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal incontinence</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bloating</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Group taking 0.075 mg RVX-100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group is taking 0.075 mg RVX-100</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group taking 0.125 mg RVX-100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group is taking 0.125 mg RVX-100</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.250 mg RVX-100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group is taking 0.250 mg RVX-100</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group is taking a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.075 mg RVX-100</intervention_name>
    <description>This group is taking the lowest dose of RVX-100</description>
    <arm_group_label>Group taking 0.075 mg RVX-100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.125 mg RVX-100</intervention_name>
    <description>This group is taking an average dose of RVX-100</description>
    <arm_group_label>Group taking 0.125 mg RVX-100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.250 mg RVX-100</intervention_name>
    <description>This group is taking the highest dose of RVX-100</description>
    <arm_group_label>0.250 mg RVX-100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>This group is taking a placebo</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Adult male or female, aged ≥18 and ≤75 years old.&#xD;
&#xD;
          -  Subject/ legal representative is able to understand and sign informed consent form.&#xD;
&#xD;
          -  Have abdominal pain severity defined as weekly average of &quot;worst abdominal pain in&#xD;
             past 24 hours&quot; score of ≥ 3.0 on a 0 to 10 point scale during the second week of the&#xD;
             Baseline phase.&#xD;
&#xD;
          -  Have IBS-D according to Rome III criteria and ≥25% of stools on the BSS inclusion&#xD;
             criteria rated as 6 or 7 during the Baseline phase.&#xD;
&#xD;
          -  Not pregnant, lactating, or breastfeeding.&#xD;
&#xD;
          -  If a female of childbearing potential, the subject must agree to remain abstinent or&#xD;
             practice two medically acceptable forms of contraception during the screening,&#xD;
             baseline, treatment, and withdrawal periods. Acceptable forms of contraception include&#xD;
             oral contraception, intrauterine devices, implantable devices, and barrier methods. If&#xD;
             a barrier method is chosen, a double barrier is required.&#xD;
&#xD;
          -  Discontinue all medications used to treat IBS symptoms (prescription and&#xD;
             non-prescription) and prescription analgesics at least two (2) weeks prior to the&#xD;
             start of the baseline period until after the final study visit. (Final study visit&#xD;
             occurs two (2) weeks after the last dose of study medication.) Acetaminophen may be&#xD;
             used as a rescue medication as long as it is carefully documented on the Case Report&#xD;
             Form (CRF). Fiber supplements are permitted if they are taken at the same frequency&#xD;
             and amount throughout the study and were taken during the four (4) weeks prior to the&#xD;
             Baseline phase. This must be documented in the source document file and the CRF.&#xD;
&#xD;
          -  Willing and able to comply with all study-related procedures, including not&#xD;
             incorporating significant changes in diet.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive for fecal ova and parasites (O&amp;P) or Clostridium difficile (ELISA) or other&#xD;
             bacterial pathogens (standard stool culture) during the Screening phase.&#xD;
&#xD;
          -  Taking medication for the treatment of IBS during the baseline phase (other than&#xD;
             acetaminophen).&#xD;
&#xD;
          -  Taking any treatment for IBS including any of the following classes of medications&#xD;
             within 2 weeks prior to baseline visit (Visit 2), or at any point during the study:&#xD;
&#xD;
               -  Antispasmodic or anticholinergic agents&#xD;
&#xD;
               -  Combination products including atropine, hyoscyamine, phenobarbital, and/or&#xD;
                  scopolamine&#xD;
&#xD;
               -  Antidepressants (such as monoamine oxidase inhibitors [MAOI], selective serotonin&#xD;
                  reuptake inhibitors [SSRIs], and tricyclic antidepressants), to include, but not&#xD;
                  limited to the following:&#xD;
&#xD;
               -  Combination products including pheniramine, phenyltoloxamine, or pyrilamine&#xD;
&#xD;
               -  Laxatives&#xD;
&#xD;
               -  Opioids/narcotic analgesics&#xD;
&#xD;
               -  Phenothiazines antipsychotics and anti-emetics&#xD;
&#xD;
          -  History of anticholinergic psychosis (psychosis associated with exposure to&#xD;
             anticholinergic medications).&#xD;
&#xD;
          -  Laboratory values greater than three times the upper limit of normal (ULN) alanine&#xD;
             transaminase (ALT/SGPT) or aspartate transaminase (AST/SGOT).&#xD;
&#xD;
          -  Laboratory values greater than two times the ULN for total bilirubin (TBil),&#xD;
             creatinine (sCr) or blood urea nitrogen (BUN).&#xD;
&#xD;
          -  Active infection with hepatitis (A, B, or C) or positive confirmatory test for HIV1,&#xD;
             or HIV2 (results of the HIV testing will be kept strictly confidential. Subject may&#xD;
             wish to undergo HIV testing as per the guidelines for HIV testing requirements in&#xD;
             India pursuant to NACO).&#xD;
&#xD;
          -  History of allergic reaction to l-hyoscyamine or atropine, or any component in the&#xD;
             formulation of the study drugs.&#xD;
&#xD;
          -  Evidence of disease (based on medical history) that could adversely affect the&#xD;
             subject's safety during participation in this study or interfere with the&#xD;
             interpretation of study results, including but not limited to: glaucoma; pyloric&#xD;
             stenosis; clinically significant benign prostatic hypertrophy; clinically significant&#xD;
             heart or lung or disease; active peptic ulcer; celiac disease; digestive tract&#xD;
             obstruction or paralysis; myasthenia gravis; inflammatory bowel disease; poorly&#xD;
             controlled hypertension; hyperthyroidism; decreased hepatic or renal function; urinary&#xD;
             retention, or lactose intolerance.&#xD;
&#xD;
          -  Use of any investigational drug within 30 days prior to the Baseline Visit (Visit 2),&#xD;
             or anytime during study.&#xD;
&#xD;
          -  History of non-compliance with treatment or clinical visit attendance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Hardi, M.D., CPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metropolitan Gastroenterology Group PC, Chevy Chase Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Metropolitan Gastroenterology Group</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <last_update_submitted>July 16, 2010</last_update_submitted>
  <last_update_submitted_qc>July 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>George Kottayil, Chief Operations Officer</name_title>
    <organization>Revogenex</organization>
  </responsible_party>
  <keyword>abdominal pain</keyword>
  <keyword>bloating</keyword>
  <keyword>diarrhea</keyword>
  <keyword>irritable bowel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

